{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:29:34Z","timestamp":1782570574455,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomized, phase IIa trial enrolled stage II\/III colon cancer patients who received adjuvant mFOLFOX6 chemotherapy. Participants were randomly allocated to 3 arms in a double-blind manner: placebo (placebo: days 1\u20133); 1-day ART (ART-123: day 1, placebo: days 2\u20133); and 3-day ART (ART-123: days 1\u20133). ART-123 (380\u00a0U\/kg\/day) or placebo was infused intravenously before each 2-week cycle of mFOLFOX6. OIPN was assessed with the Functional Assessment of Cancer Therapy\/Gynecological Oncology Group-Neurotoxicity-12 (FACT\/GOG-Ntx-12) score by participants and the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) by investigators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-nine participants (placebo <jats:italic>n<\/jats:italic>\u2009=\u200928, 1-day ART <jats:italic>n<\/jats:italic>\u2009=\u200927, 3-day ART <jats:italic>n<\/jats:italic>\u2009=\u200924) received study drugs. The least-squares mean FACT\/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART (vs. placebo: 7.3 [95% CI 1.9\u00a0to12.8, <jats:italic>p<\/jats:italic>\u2009=\u20090.009]), and 32.3 with 3-day ART (vs. placebo: 3.4 [95% CI \u2212.1 to 9.0, <jats:italic>p<\/jats:italic>\u2009=\u20090.222]). The cumulative incidence of NCI-CTCAE grade\u2009\u2265\u20092 sensory neuropathy at cycle 12 was 64.3% with placebo, 40.7% with 1-day ART (vs. placebo: \u221223.5 [95% CI \u221248.4 to 4.0], <jats:italic>p<\/jats:italic>\u2009=\u20090.108), and 45.8% with 3-day ART (vs. placebo: \u221218.5 [95% CI \u221244.2 to 9.4], <jats:italic>p<\/jats:italic>\u2009=\u20090.264). Common adverse events were consistent with those reported with mFOLFOX6; no severe bleeding adverse events occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ART-123 showed a potential preventive effect against OIPN with good tolerability. A larger study with 1-day ART is warranted.<\/jats:p>\n                <jats:p>NCT02792842, registration date: June 8, 2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-020-04135-8","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T04:02:51Z","timestamp":1600833771000},"page":"607-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy"],"prefix":"10.1007","volume":"86","clinical-trial-number":[{"clinical-trial-number":"nct02792842","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-613X","authenticated-orcid":false,"given":"Masahito","family":"Kotaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Harihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genichi","family":"Kusakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichinosuke","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"4135_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351. https:\/\/doi.org\/10.1056\/NEJMoa032709","journal-title":"N Engl J Med"},{"key":"4135_CR2","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938","journal-title":"J Clin Oncol"},{"key":"4135_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","volume":"33","author":"HJ Schmoll","year":"2015","unstructured":"Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG (2015) Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled Phase III trial. J Clin Oncol 33:3733\u20133740. https:\/\/doi.org\/10.1200\/JCO.2015.60.9107","journal-title":"J Clin Oncol"},{"key":"4135_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012. https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","journal-title":"J Clin Oncol"},{"issue":"4 Suppl 15","key":"4135_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0093-7754(03)00399-3","volume":"30","author":"A Grothey","year":"2003","unstructured":"Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30(4 Suppl 15):5\u201313. https:\/\/doi.org\/10.1016\/s0093-7754(03)00399-3","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"4135_CR6","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.3816\/CCC.2005.s.006","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(suppl 1):S38\u2013S46. https:\/\/doi.org\/10.3816\/CCC.2005.s.006","journal-title":"Clin Colorectal Cancer"},{"key":"4135_CR7","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL (2015) Clinical course of oxaliplatin-induced neuropathy: Results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33:3416\u20133422. https:\/\/doi.org\/10.1200\/JCO.2014.58.8533","journal-title":"J Clin Oncol"},{"key":"4135_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mus.20340","volume":"32","author":"AV Krishnan","year":"2005","unstructured":"Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51\u201360. https:\/\/doi.org\/10.1002\/mus.20340","journal-title":"Muscle Nerve"},{"key":"4135_CR9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109\u20133116. https:\/\/doi.org\/10.1200\/JCO.2008.20.6771","journal-title":"J Clin Oncol"},{"key":"4135_CR10","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699\u20132707. https:\/\/doi.org\/10.1200\/JCO.2013.49.1514","journal-title":"J Clin Oncol"},{"key":"4135_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"6","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135\u2013147. https:\/\/doi.org\/10.2147\/CMAR.S44261","journal-title":"Cancer Manag Res"},{"key":"4135_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Onco. https:\/\/doi.org\/10.1200\/JCO.20.01399","journal-title":"J Clin Onco"},{"key":"4135_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/clpt.2011.115","volume":"90","author":"DR Pachman","year":"2011","unstructured":"Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377\u2013387. https:\/\/doi.org\/10.1038\/clpt.2011.115","journal-title":"Clin Pharmacol Ther"},{"key":"4135_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31\u201341. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02267.x","journal-title":"J Thromb Haemost"},{"key":"4135_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10147-014-0768-1","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Saito H, Asakura H, Okamoto K, Tagawa J, Hayakawa T, Aoki N (2015) Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial. Int J Clin Oncol 20:821\u2013828. https:\/\/doi.org\/10.1007\/s10147-014-0768-1","journal-title":"Int J Clin Oncol"},{"key":"4135_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1055\/s-0037-1614900","volume":"82","author":"M Mohri","year":"1999","unstructured":"Mohri M, Sugimoto E, Sata M, Asano T (1999) The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation\u2013a comparison with other anticoagulants. Thromb Haemost 82:1687\u20131693","journal-title":"Thromb Haemost"},{"key":"4135_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1527-3466.2000.tb00055.x","volume":"18","author":"M Mohri","year":"2000","unstructured":"Mohri M (2000) ART-123: recombinant human soluble thrombomodulin. Cardiovasc Drug Rev 18:312\u2013325. https:\/\/doi.org\/10.1111\/j.1527-3466.2000.tb00055.x","journal-title":"Cardiovasc Drug Rev"},{"key":"4135_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.thromres.2016.09.011","volume":"147","author":"S Tawara","year":"2016","unstructured":"Tawara S, Sakai T, Matsuzaki O (2016) Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin. Thromb Res 147:72\u201379. https:\/\/doi.org\/10.1016\/j.thromres.2016.09.011","journal-title":"Thromb Res"},{"key":"4135_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1172\/JCI22782","volume":"115","author":"K Abeyama","year":"2005","unstructured":"Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267\u20131274. https:\/\/doi.org\/10.1172\/JCI22782","journal-title":"J Clin Invest"},{"key":"4135_CR20","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1161\/ATVBAHA.107.150631","volume":"28","author":"T Ito","year":"2008","unstructured":"Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I (2008) Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28:1825\u20131830. https:\/\/doi.org\/10.1161\/ATVBAHA.107.150631","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"880","key":"4135_CR21","doi-asserted-by":"publisher","first-page":"173196","DOI":"10.1016\/j.ejphar.2020.173196","volume":"13","author":"T Minami","year":"2020","unstructured":"Minami T, Takeda M, Sata M, Kato H, Yano K, Sakai T, Tsujita R, Kawasaki K, Ito A (2020) Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. Eur J Pharmacol 13(880):173196. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173196","journal-title":"Eur J Pharmacol"},{"key":"4135_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12974-019-1581-6","volume":"16","author":"M Tsubota","year":"2019","unstructured":"Tsubota M, Fukuda R, Hayashi Y, Miyazaki T, Ueda S, Yamashita R, Koike N, Sekiguchi F, Wake H, Wakatsuki S, Ujiie Y, Araki T, Nishibori M, Kawabata A (2019) Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin\/thrombomodulin system in rodents: negative impact of anticoagulants. J Neuroinflammation 16:199. https:\/\/doi.org\/10.1186\/s12974-019-1581-6","journal-title":"J Neuroinflammation"},{"key":"4135_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10147-015-0801-z","volume":"20","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K (2015) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207\u2013239. https:\/\/doi.org\/10.1007\/s10147-015-0801-z","journal-title":"Int J Clin Oncol"},{"key":"4135_CR24","first-page":"W1","volume":"4","author":"JA Kopec","year":"2006","unstructured":"Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, Wieand HS, Smith RE, Kuebler JP, Wolmark N (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Supp Oncol 4:W1\u2013W8","journal-title":"J Supp Oncol"},{"key":"4135_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","volume":"91","author":"JS Gewandter","year":"2018","unstructured":"Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91:403\u2013413. https:\/\/doi.org\/10.1212\/WNL.0000000000006083","journal-title":"Neurology"},{"key":"4135_CR26","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.suponc.2010.09.029","volume":"8","author":"M Sasane","year":"2010","unstructured":"Sasane M, Tencer T, French A, Maro T, Beusterien KM (2010) Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Supp Oncol 8:e15\u2013e21. https:\/\/doi.org\/10.1016\/j.suponc.2010.09.029","journal-title":"J Supp Oncol"},{"key":"4135_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00520-015-3063-4","volume":"24","author":"N Majithia","year":"2016","unstructured":"Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL (2016) National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 24:1439\u20131447. https:\/\/doi.org\/10.1007\/s00520-015-3063-4","journal-title":"Support Care Cancer"},{"key":"4135_CR28","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","volume":"25","author":"JM McCrary","year":"2017","unstructured":"McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer 25:3485\u20133493. https:\/\/doi.org\/10.1007\/s00520-017-3772-y","journal-title":"Support Care Cancer"},{"key":"4135_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/s1470-2045(18)30093-7","volume":"19","author":"TJ Iveson","year":"2018","unstructured":"Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J (2018) Three versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol 19:562\u2013578. https:\/\/doi.org\/10.1016\/s1470-2045(18)30093-7","journal-title":"Lancet Oncol"},{"key":"4135_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00280-013-2306-7","volume":"72","author":"T Kono","year":"2013","unstructured":"Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H (2013) Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72:1283\u20131290. https:\/\/doi.org\/10.1007\/s00280-013-2306-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4135_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdw206","journal-title":"Ann Oncol"},{"key":"4135_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T (2018) Duration of adjuvant chemotherapy for stage III colon cancer. New Engl J Med 378:1177\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa1713709","journal-title":"New Engl J Med"},{"key":"4135_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1200\/JCO.2017.76.0355","volume":"36","author":"T Andre","year":"2018","unstructured":"Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J (2018) Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 36:1469\u20131477. https:\/\/doi.org\/10.1200\/JCO.2017.76.0355","journal-title":"J Clin Oncol"},{"key":"4135_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/j.1552-4604.1998.tb04375.x","volume":"38","author":"M Nakashima","year":"1998","unstructured":"Nakashima M, Kanamaru M, Umemura K, Tsuruta K (1998) Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38:40\u201344. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04375.x","journal-title":"J Clin Pharmacol"},{"key":"4135_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/00498250802604074","volume":"39","author":"K Tsuruta","year":"2009","unstructured":"Tsuruta K, Kodama T, Serada M, Hori K, Inaba A, Miyake T, Kohira T (2009) Pharmacokinetics of recombinant human soluble thrombomodulin, thrombomodulin alfa in the rat. Xenobiotica 39:125\u2013134. https:\/\/doi.org\/10.1080\/00498250802604074","journal-title":"Xenobiotica"},{"key":"4135_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-015-2757-0","volume":"76","author":"M Kotaka","year":"2015","unstructured":"Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T (2015) Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemother Pharmacol 76:75\u201384. https:\/\/doi.org\/10.1007\/s00280-015-2757-0","journal-title":"Cancer Chemother Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s00280-020-04185-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04135-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:58:54Z","timestamp":1632358734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4135"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04135-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-020-04185-y","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the Original publication of the article, the authors found an error in the \u201cResults\u201d section under the heading \u201cAbstract\u201d. The corrected text is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.K., T.S., Y.U., M.T., and S.K. are employees of Asahi Kasei Pharma. G.K., T.S., and Y.U. have a patent pending (2018\u2013183447) with Asahi Kasei Pharma. Y.S., M.A., and I.H. were members of the advisory board of this study. M.K. reports personal fees from Chugai Pharma, Yakult Honsha, Merck Serono, Takeda Pharma, Taiho Pharmaceutical, and Eli Lilly Japan, outside the submitted work. Y.S. reports personal fees from Pfizer, Shionogi, Daiichi Sankyo, Nipponzoki, Kyowakirin, Ayumi-Pharma, Hisamitsu, Japan Vaccine, Bikken, GSK, Tsumura, Terumo, Astra-Zeneca, Maruishi, Ono Pharma, Aspen, Nestle, and Japan Blood Product, outside the submitted work. T.K. reports personal fees from Chugai Pharma, Takeda Pharma, Eli Lilly Japan, and Yakult Honsha, outside the submitted work. H.S. reports personal fees from Bayer, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, Eli Lilly Japan, Merck Bio Pharma, MSD, Ono Pharma, Sanofi, Taiho Pharmaceutical, Takeda, and Yakult Honsha, outside the submitted work. A.M. reports personal fees from Eli Lilly Japan, Chugai Pharma, and Takeda, outside the submitted work. Y.T. reports personal fees from Bayer, Merck Serono, Eli Lilly Japan, Chugai Pharma, Taiho Pharmaceutical, Ono Pharma, Takeda Pharma, Medicon, and Sawai Pharmaceutical, outside the submitted work. K.S. reports personal fees from Chugai Pharma, Takeda Pharma, Mochida Pharmaceutical, Merck Biopharma, Taiho Pharmaceutical, Ono Pharma, Eisai, Shionogi, Eli Lilly Japan, Daiichi Sankyo, Nihonkayaku, Kyowakirin, and Bayer Yakuhin, outside the submitted work. T.F. reports grants and personal fees from Oncolys BioPharma, outside the submitted work. T.M. reports personal fees from Chugai Pharma, Mitsubishi Tanabe Pharma, Miyarisan Pharmaceutical, EA Pharma, AbbVie GK, Kyorin Pharmaceutical, and Sanofi K.K., and other support from Kinshukai Medical, outside the submitted work. Y.H., N.N., and N.K. have nothing to disclose. M.A. reports grants from Kyowa Kirin, outside the submitted work. I.H. reports grants and personal fees from Chugai Pharma, Taiho Pharma, Daiichi Sankyo, Yakult Honsha, and Ono Pharma, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and with Good Clinical Practice guidelines. The protocol of this study was approved by the institutional review board of each participating site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}